One hundred seventy-eight patients with cancer were treated with amygdalin (Laetrile) plus a "metabolic therapy" program consisting of diet, enzymes, and vitamins. The great majority of these patients were in good general condition before treatment. None was totally disabled or in preterminal condition. One third had not received any previous chemotherapy. The pharmaceutical preparations of amygdalin, the dosage, and the schedule were representative of past and present Laetrile practice. No substantive benefit was observed in terms of cure, improvement or stabilization of cancer, improvement of symptoms related to cancer, or extension of life span. The hazards of amygdalin therapy were evidenced in several patients by symptoms of cyanide toxicity or by blood cyanide levels approaching the lethal range. Patients exposed to this agent should be instructed about the danger of cyanide poisoning, and their blood cyanide levels should be carefully monitored. Amygdalin (Laetrile) is a toxic drug that is not effective as a cancer treatment.
This article has been cited by other articles:
Moss, R. W.
(2008). Enzymes, Trophoblasts, and Cancer: The Afterlife of an Idea (1924-2008). Integr Cancer Ther
7: 262-275
[Abstract]
Stern, P. J.
(2007). Hattage. JBJS
89: 2803-2809
[Full Text]
Cassileth, B. R., Deng, G. E., Gomez, J. E., Johnstone, P. A. S., Kumar, N., Vickers, A. J.
(2007). Complementary Therapies and Integrative Oncology in Lung Cancer: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition). Chest
132: 340S-354S
[Abstract][Full Text]
Bromley, J., Hughes, B. G., Leong, D. C., Buckley, N. A
(2005). Life-Threatening Interaction Between Complementary Medicines: Cyanide Toxicity Following Ingestion of Amygdalin and Vitamin C. The Annals of Pharmacotherapy
39: 1566-1569
[Abstract][Full Text]
Moss, R. W.
(2005). Patient Perspectives: Tijuana Cancer Clinics in the Post-NAFTA Era. Integr Cancer Ther
4: 65-86
[Abstract]
Schmidt, K., Ernst, E.
(2004). Assessing websites on complementary and alternative medicine for cancer. Ann Oncol
15: 733-742
[Abstract][Full Text]
Vickers, A.
(2004). Alternative Cancer Cures: "Unproven" or "Disproven"?. CA Cancer J Clin
54: 110-118
[Abstract][Full Text]
Cassileth, B. R., Deng, G.
(2004). Complementary and Alternative Therapies for Cancer. The Oncologist
9: 80-89
[Abstract][Full Text]
Markman, M.
(2002). Safety Issues in Using Complementary and Alternative Medicine. JCO
20: 39s-41
[Abstract][Full Text]
Cohen, M. H., Eisenberg, D. M.
(2002). Potential Physician Malpractice Liability Associated with Complementary and Integrative Medical Therapies. ANN INTERN MED
136: 596-603
[Abstract][Full Text]
Markman, M.
(2001). Interactions Between Academic Oncology and Alternative/Complementary/Integrative Medicine: Complex But Necessary. JCO
19: 52s-53
[Full Text]
Jacobson, J. S., Workman, S. B., Kronenberg, F.
(2000). Research on Complementary/Alternative Medicine for Patients With Breast Cancer: A Review of the Biomedical Literature. JCO
18: 668-668
[Abstract][Full Text]
Verhoef, M. J., Hagen, N., Pelletier, G., Forsyth, P.
(1999). Alternative therapy use in neurologic diseases: Use in brain tumor patients. Neurology
52: 617-617
[Abstract][Full Text]
Dyer, H. R.
(1997). Homeopathy--The Emperor's Medicine. Arch Intern Med
157: 1139-1140
[Abstract]
Ferguson, J. H., Dubinsky, M., Kirsch, P. J.
(1993). Court-Ordered Reimbursement for Unproven Medical Technology: Circumventing Technology Assessment. JAMA
269: 2116-2121
[Abstract]
Holmes, S.
(1992). Have Alternative Methods Got a Place in the Treatment of Cancer ?. The Journal of the Royal Society for the Promotion of Health
112: 15-19
CASSILETH, B. R., LUSK, E. J., STROUSE, T. B., BODENHEIMER, B. J.
(1984). Contemporary Unorthodox Treatments in Cancer Medicine: A Study of Patients, Treatments, and Practitioners. ANN INTERN MED
101: 105-112
[Abstract]
Previous
